{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:55:56Z","timestamp":1784231756633,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"13-14","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ALF-agreement","award":["ALFGBG-966074"],"award-info":[{"award-number":["ALFGBG-966074"]}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["23 2975"],"award-info":[{"award-number":["23 2975"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["20 1293"],"award-info":[{"award-number":["20 1293"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-02636"],"award-info":[{"award-number":["2021-02636"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as 177Lu-octreotate and 177Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from 177Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with 177Lu-octreotide on urinary levels of retinol-binding protein 4 (RBP4) and creatinine (Cr). Mice received 60\u00a0MBq 177Lu-octreotide intravenously, plus none, one, or several rA1M injections. Urinary RBP4 and Cr concentrations were measured after 6\u201310\u00a0weeks. Urinary RBP4 was similar in all groups, but with large individual variations in some groups. RBP4\/Cr may be a useful early-responding biomarker. Further investigations are needed to determine effects of long-term kidney protection by rA1M schedules.<\/jats:p>","DOI":"10.1093\/rpd\/ncaf090","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:43:23Z","timestamp":1756392203000},"page":"995-1005","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide"],"prefix":"10.1093","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2982-3275","authenticated-orcid":false,"given":"Nishte","family":"Rassol","sequence":"first","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ytterbrink","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Pettersson","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Al-Awar","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Bakr","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]},{"name":"Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital , SE-413 45 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-2925","authenticated-orcid":false,"given":"Magnus","family":"Gram","sequence":"additional","affiliation":[{"name":"Paediatrics, Department of Clinical Sciences Lund, Lund University, SE-221 85 Lund, and Department of Neonatology, Sk\u00e5ne University Hospital , SE-221 84 Lund ,","place":["Sweden"]},{"name":"Biofilms\u2014Research Centre for Biointerfaces, Department of Biomedical Science, Faculty of Health and Society, Malm\u00f6 University , SE-205 06 Malm\u00f6 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Spetz","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-4368","authenticated-orcid":false,"given":"Eva","family":"Forssell-Aronsson","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , SE-413 45 Gothenburg ,","place":["Sweden"]},{"name":"Sahlgrenska Centre for Cancer Research, Sahlgrenska Academy, University of Gothenburg , Box 425, SE-405 30 Gothenburg ,","place":["Sweden"]},{"name":"Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital , SE-413 45 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025082810431535800_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-017-0567-8","article-title":"Radionuclide therapy for neuroendocrine tumors","volume":"19","author":"Cives","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2025082810431535800_ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","article-title":"Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours","volume":"102-103","author":"Geenen","year":"2021","journal-title":"Nucl Med Biol"},{"key":"2025082810431535800_ref3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1667\/RR3105","article-title":"Renal toxicity after radionuclide therapy","volume":"161","author":"Lambert","year":"2004","journal-title":"Radiat Res"},{"key":"2025082810431535800_ref4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025082810431535800_ref5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J Nucl Med"},{"key":"2025082810431535800_ref6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000336086","article-title":"Radionuclide therapy via SSTR: future aspects from experimental animal studies","volume":"97","author":"Forssell-Aronsson","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2025082810431535800_ref7","doi-asserted-by":"publisher","first-page":"30309","DOI":"10.3390\/ijms161226234","article-title":"Human anti-oxidation protein A1M\u2014a potential kidney protection agent in peptide receptor radionuclide therapy","volume":"16","author":"Ahlstedt","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2025082810431535800_ref8","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10081271","article-title":"Kidney protection with the radical scavenger alpha1-microglobulin (A1M) during peptide receptor radionuclide and radioligand therapy","volume":"10","author":"Kristiansson","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"2025082810431535800_ref9","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.2967\/jnumed.118.225243","article-title":"Recombinant \u03b1(1)-microglobulin is a potential kidney protector in (177)Lu-octreotate treatment of neuroendocrine tumors","volume":"60","author":"Andersson","year":"2019","journal-title":"J Nucl Med"},{"key":"2025082810431535800_ref10","first-page":"333","article-title":"Biodistribution and pharmacokinetics of recombinant \u03b11-microglobulin and its potential use in radioprotection of kidneys","volume":"5","author":"Ahlstedt","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2025082810431535800_ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165825","article-title":"\u0391(1)-microglobulin (A1M) protects human proximal tubule epithelial cells from Heme-induced damage In vitro","volume":"21","author":"Kristiansson","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082810431535800_ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2015.00011","article-title":"A1M\/\u03b11-microglobulin is proteolytically activated by myeloperoxidase, binds its heme group and inhibits low density lipoprotein oxidation","volume":"6","author":"Cederlund","year":"2015","journal-title":"Front Physiol"},{"key":"2025082810431535800_ref13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.placenta.2011.01.017","article-title":"Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by \u03b11-microglobulin","volume":"32","author":"May","year":"2011","journal-title":"Placenta"},{"key":"2025082810431535800_ref14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00417-012-2113-6","article-title":"Vitreous levels of oxidative stress biomarkers and the radical-scavenger \u03b11-microglobulin\/A1M in human rhegmatogenous retinal detachment","volume":"251","author":"Cederlund","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025082810431535800_ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biom13060928","article-title":"Recombinant \u03b1(1)-microglobulin (rA1M) protects against hematopoietic and renal toxicity, alone and in combination with amino acids, in a (177)Lu-DOTATATE mouse radiation model","volume":"13","author":"Alattar","year":"2023","journal-title":"Biomolecules"},{"key":"2025082810431535800_ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020263","article-title":"(177)Lu-PSMA-617 therapy in mice, with or without the antioxidant \u03b1(1)-microglobulin (A1M), including kidney damage assessment using (99m)Tc-MAG3 imaging","volume":"11","author":"Kristiansson","year":"2021","journal-title":"Biomolecules"},{"key":"2025082810431535800_ref17","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1038\/s41598-023-32091-9","article-title":"Co-administration with A1M does not influence apoptotic response of (177)Lu-octreotate in GOT1 neuroendocrine tumors","volume":"13","author":"Rassol","year":"2023","journal-title":"Sci Rep"},{"key":"2025082810431535800_ref18","doi-asserted-by":"publisher","first-page":"F640","DOI":"10.1152\/ajprenal.00264.2016","article-title":"An evaluation of the antioxidant protein \u03b11-microglobulin as a renal tubular cytoprotectant","volume":"311","author":"Zager","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025082810431535800_ref19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0270-9295(03)00093-7","article-title":"Radiation nephropathy","volume":"23","author":"Cohen","year":"2003","journal-title":"Semin Nephrol"},{"key":"2025082810431535800_ref20","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1681\/ASN.2004110945","article-title":"Renal tubulointerstitial changes after internal irradiation with \u03b1-particle\u2013emitting actinium daughters","volume":"16","author":"Jaggi","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025082810431535800_ref21","first-page":"120","article-title":"Early diagnostic value of urinary NGAL in acute kidney injury in septic patients","volume":"28","author":"Hu","year":"2022","journal-title":"Altern Ther Health Med"},{"key":"2025082810431535800_ref22","doi-asserted-by":"publisher","first-page":"e10572","DOI":"10.34172\/npj.2023.10572","article-title":"Kidney injury molecule-1; is it a predictive marker for renal diseases?","volume":"12","author":"Anandkumar","year":"2023","journal-title":"J Nephropharmacol"},{"key":"2025082810431535800_ref23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/clinchem\/33.6.775","article-title":"Assessment of urinary retinol-binding protein as an index of proximal tubular injury","volume":"33","author":"Bernard","year":"1987","journal-title":"Clin Chem"},{"key":"2025082810431535800_ref24","doi-asserted-by":"publisher","first-page":"9878","DOI":"10.3390\/ijerph19169878","article-title":"The clinical significance of urinary retinol-binding protein 4: a review","volume":"19","author":"Ratajczyk","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025082810431535800_ref25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13550-014-0059-x","article-title":"Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate","volume":"4","author":"Dalmo","year":"2014","journal-title":"EJNMMI Res"},{"key":"2025082810431535800_ref26","volume-title":"Optimisation of radionuclide therapy by reduction of normal tissue damage, PhD Thesis, in Institute of Clinical Sciences. Department of Radiation Physics","author":"Andersson","year":"2022"},{"key":"2025082810431535800_ref27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pep.2006.10.023","article-title":"Production of recombinant human \u03b11-microglobulin and mutant forms involved in chromophore formation","volume":"53","author":"Kwasek","year":"2007","journal-title":"Protein Expr Purif"},{"key":"2025082810431535800_ref28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbapap.2015.10.002","article-title":"Structural and biochemical characterization of two heme binding sites on \u03b11-microglobulin using site directed mutagenesis and molecular simulation","volume":"1864","author":"Rutardottir","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"2025082810431535800_ref29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3109\/0284186X.2015.1027001","article-title":"The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL\/6N mice","volume":"55","author":"Sch\u00fcler","year":"2016","journal-title":"Acta Oncol"},{"key":"2025082810431535800_ref30","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1681\/ASN.2008060617","article-title":"Reduced production of creatinine limits its use as marker of kidney injury in sepsis","volume":"20","author":"Doi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025082810431535800_ref31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/2191-219X-2-49","article-title":"Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy","volume":"2","author":"Larsson","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2025082810431535800_ref32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3892\/or.2011.1494","article-title":"Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2","volume":"27","author":"Dalmo","year":"2012","journal-title":"Oncol Rep"},{"key":"2025082810431535800_ref33","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","article-title":"Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues","volume":"37","author":"Rolleman","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2025082810431535800_ref34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00259-005-1793-0","article-title":"Localisation and mechanism of renal retention of radiolabelled somatostatin analogues","volume":"32","author":"Melis","year":"2005","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2025082810431535800_ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2022.0032","article-title":"Biomarkers for early detection and predicting outcomes in acute kidney injury","volume":"83","author":"Cottam","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"key":"2025082810431535800_ref36","doi-asserted-by":"publisher","first-page":"e0136204","DOI":"10.1371\/journal.pone.0136204","article-title":"Potential biomarkers for radiation-induced renal toxicity following 177Lu-octreotate administration in mice","volume":"10","author":"Sch\u00fcler","year":"2015","journal-title":"PLoS One"},{"key":"2025082810431535800_ref37","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1089\/ars.2018.7517","article-title":"Protection of kidney function with human antioxidation protein \u03b1(1)-microglobulin in a mouse (177)Lu-DOTATATE radiation therapy model","volume":"30","author":"Kristiansson","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"2025082810431535800_ref38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000518240","article-title":"Urine Alpha-1-microglobulin levels and acute kidney injury, mortality, and cardiovascular events following cardiac surgery","volume":"52","author":"Amatruda","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025082810431535800_ref39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000309421","article-title":"Serum and urinary biomarkers of acute kidney injury","volume":"29","author":"Lisowska-Myjak","year":"2010","journal-title":"Blood Purif"},{"key":"2025082810431535800_ref40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxlet.2003.11.009","article-title":"alpha1-microglobulin as a promising marker of cadmium-induced tubular dysfunction, possibly better than beta2-microglobulin","volume":"148","author":"Moriguchi","year":"2004","journal-title":"Toxicol Lett"},{"key":"2025082810431535800_ref41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.medcle.2020.06.062","article-title":"Alpha-1-microglobulin: prognostic value in chronic kidney disease","volume":"157","author":"Robles","year":"2021","journal-title":"Med Cl\u00edn (Barc)"},{"key":"2025082810431535800_ref42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/B978-0-12-803014-1.00006-6","article-title":"Biomarkers in acute kidney injury","author":"Edelstein","year":"2017","journal-title":"Biomarkers of Kidney Disease"},{"key":"2025082810431535800_ref43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejcts.2010.05.044","article-title":"Comparison of urinary neutrophil glucosaminidase-associated lipocalin, cystatin C, and \u03b11-microglobulin for early detection of acute renal injury after cardiac surgery","volume":"39","author":"Heise","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025082810431535800_ref44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40620-022-01499-3","article-title":"Elevated urinary alpha-1 microglobulin levels are associated with decreased survival among chronic kidney disease patients: a real-world population study","volume":"36","author":"Oliva-Damaso","year":"2023","journal-title":"J Nephrol"},{"key":"2025082810431535800_ref45","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ekir.2019.07.009","article-title":"Pilot study of renal urinary biomarkers for diagnosis of CKD of uncertain etiology","volume":"4","author":"Fernando","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2025082810431535800_ref46","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ekir.2023.02.1071","article-title":"Recombinant alpha-1-microglobulin (RMC-035) to prevent acute kidney injury in cardiac surgery patients: phase 1b evaluation of safety and pharmacokinetics","volume":"8","author":"Weiss","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025082810431535800_ref47","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.3390\/ijms25137480","article-title":"Effects of recombinant \u03b11-microglobulin on early proteomic response in risk organs after exposure to 177Lu-octreotate","volume":"25","author":"Ytterbrink","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Radiation Protection Dosimetry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rpd\/article-pdf\/201\/13-14\/995\/64149004\/ncaf090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rpd\/article-pdf\/201\/13-14\/995\/64149004\/ncaf090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:43:24Z","timestamp":1756392204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rpd\/article\/201\/13-14\/995\/8242659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":47,"journal-issue":{"issue":"13-14","published-online":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1093\/rpd\/ncaf090","relation":{},"ISSN":["0144-8420","1742-3406"],"issn-type":[{"value":"0144-8420","type":"print"},{"value":"1742-3406","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,26]]}}}